ClinicalTrials.gg
CompletedNCT00396292Updated Feb 5, 2018Results posted

Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia

A Phase 3 interventional study of Oral iron tablets and VIT-45 in Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2018-02-05.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
361
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.

Enrollment
15th of 54
361 · median 156
Started
2005
with 4 others
Phase 3
23 of 54
none open now
Registered
4th of 54
by date
Lead sponsor
11 of 54
American Regent, Inc.

Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 15th largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 4th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing ferric carboxymaltose in Anemia, or all of them as a file.
02

Study summary

This study compares the safety and efficacy of intravenous iron vs oral iron in subjects who display postpartum anemia.

Read the detailed description

This is an open label, Phase III, randomized, active controlled study of intravenous iron vs oral iron in anemic post partum patients.

03

Conditions studied

  • Anemia

Browse trials for

Keywords

  • Anemia
  • postpartum
  • Postpartum anemia
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female Subjects able to give consent
  • Post partum patients
  • Baseline Hbg\< /= 10
  • Agree to practice
  • Demonstrate willingness to comply with protocol restrictions

Exclusion criteria

Exclusion Criteria:

  • Known reaction to oral or IV iron (VIT-45)
  • Documented history of discontinuing oral iron
  • Significant bleeding
  • History of anemia other that iron deficiency anemia
  • Severe Psychiatric disorders
  • Active severe infection
  • Known antigen or Hep C viral antibody or active hepatitis
  • Known antibody
  • Received product within 30 days
  • Alcohol abuse
  • Hemochromatosis or other iron storage disorder
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
361 participants (actual)

Study arms

  • Experimental
    VIT-45

    A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered

    Drug: VIT-45

  • Active comparator
    Oral iron tablets

    325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42

    Drug: Oral iron tablets

Interventions

  • 325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42

    Also known as: Ferrous Sulfate

  • DrugVIT-45

    A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Achieved 'Success' Meaning a ≥ 2.0 Increase in Hemoglobin

    Time frame: anytime between baseline and the end of study or time to intervention

07

Results

Posted Dec 10, 2013

Participant flow

Hospitals and medical clinics

Participant flow — Overall Study
MilestoneVIT-45Oral Iron Tablets
Started174178
Completed165162
Not completed916

Outcome measures

PrimaryNumber of Subjects Who Achieved 'Success' Meaning a ≥ 2.0 Increase in Hemoglobin
Time frame:
anytime between baseline and the end of study or time to intervention
Reported as:
Number · participants
Number of Subjects Who Achieved 'Success' Meaning a ≥ 2.0 Increase in Hemoglobin
participantsVIT-45Oral Iron Tablets
Number of Subjects Who Achieved 'Success' Meaning a ≥ 2.0 Increase in Hemoglobin162159

Adverse events

Collected over 9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VIT-45—4/174 (2.3%)40/174 (23%)
Oral Iron Tablets—4/178 (2.2%)61/178 (34.3%)
Most frequent serious events
Most frequent serious events
EventVIT-45Oral Iron Tablets
Peripartum cardiomyopathyPregnancy, puerperium and perinatal conditions1/1740/178
Cardiac failureCardiac disorders1/1740/178
Postoperative infectionInfections and infestations1/1740/178
AppendicitisInfections and infestations1/1740/178
CholecystitisHepatobiliary disorders1/1740/178
Cardiac failure congestiveCardiac disorders0/1741/178
ThrombophlebitisVascular disorders0/1741/178
Major depressionPsychiatric disorders0/1741/178
CholelithiasisHepatobiliary disorders0/1741/178
Most frequent other events
Most frequent other events
EventVIT-45Oral Iron Tablets
HeadacheNervous system disorders30/17421/178
ConstipationGastrointestinal disorders7/17425/178
NauseaGastrointestinal disorders3/17415/178

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)VIT-45Oral Iron TabletsTotal
<=18 years151631
Between 18 and 65 years159162321
>=65 years000
Age, Continuous
Age, Continuous(years)VIT-45Oral Iron TabletsTotal
Mean26.93 ± 6.3626.03 ± 5.9526.41 ± 6.17
Sex: Female, Male
Sex: Female, Male(Participants)VIT-45Oral Iron TabletsTotal
Female174178352
Male000
Region of Enrollment
Region of Enrollment(participants)VIT-45Oral Iron TabletsTotal
United States174178352
08

Study locations

1 site
  • Luitpold Pharmaceuticals
    Norristown, Pennsylvania 19403, United States
09

References and documents

Publications

  • Baker JB, Seid MH, Van Wyck DB, Mangione A. Ferric Carboxymaltose, a New IV Iron Agent for Postpartum Anemia. Society for the Advancement of Blood Management 6th Annual Meeting 2007.
  • Baker JB, Seid MH, Van Wyck DB, Dinh Q. Ferric Carboxymaltose, a New IV Iron Agent for Treating Postpartum Women with Iron Deficiency Anemia. Society for the Advancement of Blood Management 6th Annual Meeting 2007.
  • Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007 Aug;110(2 Pt 1):267-78. doi: 10.1097/01.AOG.0000275286.03283.18. Erratum In: Obstet Gynecol. 2008 Apr;111(4):996. PubMed 17666600 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Nov 2005 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 8 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2006
First posted
Nov 6, 2006
Start
Feb 2005
Primary completionActual
Nov 2005
CompletionActual
Feb 2006
Results first posted
Dec 10, 2013
Last update
Feb 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00396292
Responsible party
Sponsor
First posted
Nov 6, 2006
Start date
Feb 2005
Primary completion
Nov 2005
Completion
Feb 2006
Results posted
Dec 10, 2013
Last update
Feb 5, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion